EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Artificial Intelligence and Deep/Machine Learning(AI & D/ML) or Artificial Neural Network (ANN): Implications for pharmaceutical product development processes
Producing pharmaceutical products without untoward effects but with desired qualities is not only the very basic requirement set by regulatory authorities but also indirectly decides the success of the pharma industry The pharmaceutical product development process is a combined and coordinated work from numerous divisions of the pharma industry which usually starts
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
The earliest example of in vivo expression of exogenous mRNA was by direct intramuscular injection in mice without the aid of a delivery vehicle This appears to defy what is known about nucleic acids being that they are large polar and metabolically unstable drugs that do not cross cell membranes However since cytoplasmic delivery is essential for mRNA transcription
Efficiency in Bioprocessing: Unveiling Upstream and Downstream Operations
Bioprocessing plays a crucial role in the pharmaceutical biotechnology and healthcare industries ensuring the efficient production of biologics vaccines and other biobased products
Unveiling Opportunities: Trends and Analysis in the European Pharmaceutical Market
The European pharmaceutical market stands at the forefront of global healthcare playing a pivotal role in the development and distribution of lifesaving medications Renowned for its innovative research and commitment to healthcare excellence the industry is experiencing dynamic shifts that demand the unwavering attention of BB stakeholders With a profound emphasis on precision medicine digital hea...
Fundamentals of Clinical Pharmacology: Understanding Drug Actions and Ensuring Safety
Clinical pharmacology offers the interface between the philosophies of pharmacology and its application in the actual sense in patient care Fundamentally it is the science which examines the activities of drugs how drugs communicate with biological systems and how such communications result in treatment outcomes or adverse events Clinical pharmacology principles are needed to make sense of how m...
How Mass Spectrometers Are Transforming the Study of Metabolomics
The mechanism of metabolomics can be described as a relatively young science which is rather popular in modern science and investigates metabolites which are the small molecules that take part in the metabolic processes inside the living organism This discipline therefore has great potential as a tool in proactively unraveling a diverse range of biological occurrences disease processes or even tre...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases
Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Ruvanthi N. Kularatne
Rachael M. Crist
Stephan T. Stern
The earliest example of in vivo expression of exogenous mRNA is by direct intramuscular injection in mice without the aid of a delivery vehicle. The current state of the art for therapeutic nucleic ac...
-
2
Efficiency in Bioprocessing: Unveiling Upstream and Downstream Operations
Kate Williamson
Efficiency in Bioprocessing: Unveiling Upstream and Downstream Operations explores the key aspects of bioprocessing efficiency, covering upstream and downstream operations, integration strategies, fut...
-
3
Unveiling Opportunities: Trends and Analysis in the European Pharmaceutical Market
Kate Williamson
The European pharmaceutical market is undergoing transformative shifts, marked by a biopharmaceutical boom, digital health integration, and precision medicine advancements. Stakeholders must navigate...
-
4
Fundamentals of Clinical Pharmacology: Understanding Drug Actions and Ensuring Safety
Kate Williamson
This article will discuss the fundamentals of clinical pharmacology, drug effects, pharmacodynamics and pharmacokinetics. It highlights evidence-based practice of drug safety, pharmacovigilance, and r...
-
5
How Mass Spectrometers Are Transforming the Study of Metabolomics
Kate Williamson
Mass spectrometry (MS) is being rapidly applied to metabolomics because both the sensitivity and accuracy of analysis of metabolites can easily be achieved using this technique. It refines knowledge o...
press releases Read more...
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
MacroGenics Inc a clinicalstage biopharmaceutical company focused on developing innovative antibodybased therapeutics for the treatment of cancer today announced that the first patient has been dosed in the Phase study of MGC a firstinclass antibodydrug conjugate
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Corporation a global leader in cell therapy today announced that the US Food and Drug Administration FDA has cleared the investigational new drug IND application for LB an investigational in vivo CART therapy designed to generate CDCD dualtargeting chimeric antigen receptor T
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics Inc a latestage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs today announced the submission of an Investigational New Drug IND application to the US Food and Drug Administration FDA to evaluate EIK for the t...
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials
AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support
Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments
Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments
Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
Insitro an AI company unlocking causal human biology to systematically generate highvalue therapeutics to treat grievous illness today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunctionassociated steat...
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial
Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics




